Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

Fig. 3

Maximum change in tumor size from baseline in individual patients over the course of treatment. Changes in tumor size (diameter) were assessed in patients treated with mFOLFOX-6 plus cetuximab (FOLFOX + Cmab) or XELOX plus cetuximab (XELOX + Cmab). Tumor shrinkage relative to baseline was observed in 88.7 % of patients, revealing the strength of combination therapy with cetuximab and oxaliplatin-based chemotherapy

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us